BR9911457A - Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv - Google Patents

Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv

Info

Publication number
BR9911457A
BR9911457A BR9911457-7A BR9911457A BR9911457A BR 9911457 A BR9911457 A BR 9911457A BR 9911457 A BR9911457 A BR 9911457A BR 9911457 A BR9911457 A BR 9911457A
Authority
BR
Brazil
Prior art keywords
hiv
drug
dideoxyuridine
treatment
combination
Prior art date
Application number
BR9911457-7A
Other languages
English (en)
Inventor
Raymond Schinazi
Martin L Bryant
Maureen W Myers
Original Assignee
Univ Emory
Novirio Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Novirio Pharmaceuticals Ltd filed Critical Univ Emory
Publication of BR9911457A publication Critical patent/BR9911457A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE 3'-AZIDO-2',3'-DIDEOXIURIDINA EM COMBINAçãOCOM DROGAS ANTI-HIV ADICIONAIS PARA A MANUFATURADE UM MEDICAMENTO PARA O TRATAMENTO DE HIV". Foidescoberto que 3' -azido-2',3' -dideoxiuridina (CS87) induz umamutação transitória no HIV-1 no 70<198> códon (K para R, ouseja, lisina para arginina) da região de transcriptase reversa dovírus. Baseado nessa descoberta, é fornecido um método ecomposição para o tratamento de HIV que inclui a administraçãode CS-87 ou sua pró-droga ou sal farmaceuticamente aceitáveis aum humano que necessite de terapia em combinação oualternância com uma droga que induz uma mutação no HIV emuma outra localização que não o 700 códon da região detranscriptase reversa. Essa invenção pode ser praticadareferindo-se aos padrões de mutação publicados para drogasanti-HIV conhecidas, ou determinando-se o padrão de mutaçãopara uma nova droga.
BR9911457-7A 1998-06-24 1999-06-24 Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv BR9911457A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9055298P 1998-06-24 1998-06-24
US13212699P 1999-04-30 1999-04-30
PCT/US1999/014329 WO1999066936A1 (en) 1998-06-24 1999-06-24 Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Publications (1)

Publication Number Publication Date
BR9911457A true BR9911457A (pt) 2001-12-11

Family

ID=26782403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911457-7A BR9911457A (pt) 1998-06-24 1999-06-24 Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv

Country Status (8)

Country Link
US (2) US6194391B1 (pt)
EP (1) EP1089741A1 (pt)
JP (2) JP2002518452A (pt)
AU (1) AU4716299A (pt)
BR (1) BR9911457A (pt)
CA (1) CA2335617C (pt)
MX (1) MXPA00012842A (pt)
WO (1) WO1999066936A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
JP2002518452A (ja) * 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
DK2415776T3 (en) * 1998-08-10 2016-07-04 Novartis Ag Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B
GB9820420D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
EP1731155A3 (en) * 1999-01-22 2007-02-21 Emory University Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
US7115584B2 (en) 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
DK1143976T3 (da) * 1999-01-22 2006-09-04 Univ Emory Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
WO2001074329A2 (en) 2000-03-30 2001-10-11 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
WO2003045327A2 (en) * 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
BR0314259A (pt) * 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
US7148349B2 (en) * 2002-10-31 2006-12-12 Metabasis Therapeutics, Inc. Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
ES2308136T3 (es) * 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
CA2600025A1 (en) * 2005-03-07 2006-09-14 Adventrx Pharmaceuticals, Inc. The use of thiophosphonoformic acid and nrtis to treat viral infections
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099010A (en) 1983-01-17 1992-03-24 Research Corporation Intermediates in the preparation of 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
GB2181128A (en) 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5084445A (en) * 1986-05-01 1992-01-28 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
DE3840044A1 (de) 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
GR1000618B (el) * 1989-03-17 1992-08-31 Oncogen Μεθοδος αναστολης hiv χρησιμοποιωντας συνεργιστικους συνδυασμους νουκλεοσιδικων παραγωγων.
DE3916072A1 (de) 1989-05-17 1990-11-22 Thera Ges Fuer Patente Ceramidderivate und ihre verwendung als inhibitoren der sphingolipidsynthese
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
US5232837A (en) 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5317009A (en) * 1991-08-26 1994-05-31 New York University Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ES2113549T3 (es) * 1992-08-19 1998-05-01 Schering Corp Metodo para inhibir la replicacion de vih empleando il-4.
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
EP0651817B1 (en) 1993-05-06 2000-09-20 Dsm N.V. Enzymatic synthesis of ceramides and hybrid ceramides
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
JPH0797324A (ja) * 1993-06-03 1995-04-11 Mitsubishi Chem Corp 抗ウイルス剤
US5616578A (en) * 1993-08-26 1997-04-01 The Dupont Merck Pharmaceutical Company Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
DE69410814T2 (de) 1993-10-18 1998-11-12 Virginia Tech Intell Prop Synthese von sphingosinen
US5637589A (en) * 1993-10-29 1997-06-10 University Of North Carolina At Chapel Hill Suksdorfin, analogs, compositions thereof, and methods for making and using thereof
DK0726960T3 (da) 1993-11-03 2003-04-22 Cosmoferm Bv Mikrobestammer, som danne sphingolipidbaser
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5811390A (en) * 1995-08-22 1998-09-22 Metatron, Inc. Use of beta HCG for the control of retroviral infection
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
WO1997027332A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
JPH09323932A (ja) * 1996-01-31 1997-12-16 Sankyo Co Ltd エイズ治療剤又は予防剤
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
WO1997037657A1 (fr) * 1996-04-04 1997-10-16 Shionogi & Co., Ltd. Composition anti-vih contenant un derive d'imidazole
EP0914125A4 (en) * 1996-05-02 2000-04-05 Merck & Co Inc HIV protease inhibitors, useful in AIDS treatment.
KR20000022225A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘 및(또는)1592u89를 포함하는 배합물
CA2261619C (en) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
CA2270963A1 (en) * 1996-11-08 1998-05-14 The Dupont Merck Pharmaceutical Company (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl] -2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
US5849793A (en) * 1997-08-15 1998-12-15 The Picower Institute For Medical Research HIV matrix protein tyrosine position 29 pocket binders
JP2002518452A (ja) * 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用

Also Published As

Publication number Publication date
US20010009906A1 (en) 2001-07-26
EP1089741A1 (en) 2001-04-11
WO1999066936A1 (en) 1999-12-29
US6194391B1 (en) 2001-02-27
JP2010280724A (ja) 2010-12-16
MXPA00012842A (es) 2004-06-22
JP2002518452A (ja) 2002-06-25
CA2335617C (en) 2009-12-15
US6602664B2 (en) 2003-08-05
WO1999066936A9 (en) 2000-04-06
AU4716299A (en) 2000-01-10
CA2335617A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
BR9911457A (pt) Uso de 3&#39;-azida-2&#39;, 3&#39;-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
BR0113927A (pt) Processos para retardar a recorrência dos sintomas de herpes vìrus
TR200003333T2 (tr) Ensülin direngenliği ve hiperglisemi tedavisinde yararlı benzotiyofenler
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
MY101207A (en) Treatment of diseases caused by retroviruses
DK0413622T3 (da) Albuminderivater med terapeutiske virkninger
BR0207752A (pt) Composto, sais de sódio, cálcio, potássio, magnésio, colina, etanolamina e trietilamina dos compostos, formas dos mesmos, métodos de tratamento ou de prevenção de uma infeção viral em um ser humano e de tratamento dos vìrus mutantes hiv uso de um composto, composição farmacêutica, e, processo para a preparação dos compostos
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0114483A (pt) Derivado de pirazol para tratamento de doenças viróticas
KR910700045A (ko) Hiv 감염 관련 질병의 치료
DE60022036D1 (de) Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
SE9002500D0 (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
DE3780016D1 (de) Pharmazeutisches praeparat mit 3&#39;-desoxythymidin-2&#39;-en(3&#39;-desoxy-2&#39;,3&#39;-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen.
BR0213292A (pt) tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
KR970025615A (ko) 암 전이 억제제
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
ES2123156T3 (es) Compuestos y procedimientos de inhibicion de hiv y virus semejantes.
DK1001792T3 (da) Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
ES2053953T3 (es) Uso de fracciones de heparina o fragmentos de heparina.
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
Kirk et al. Tocopherol administration to patients with Dupuytren's contracture; effect on plasma tocopherol levels and degree of contracture.
BR9712614A (pt) Composição farmacêutica,processos para aumentar e manter a homogeneidade de uma composição farmac&amp;eutica,para tratar,reverter,reduzir ou inibir infeccões retrovirais e para preparação de uma composição farmacêutica,uso de lamivudina ou de um derivado farmaceuticamenete aceitável da mesma,de zidovudina,ou de um derivado farmaceuticamente aceitável da mesma e de um agente de deslizamento farmaceuticamente aceitável,e, artigo de amnufatura.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1942 DE 25/03/2008.